Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

AbbVie Calls For US FDA Hearing On Biosimilars Interchangeability

This article was originally published in SRA

Executive Summary

While the US Food and Drug Administration had pledged to provide biosimilar makers with guidance in 2015 outlining what is needed for products to demonstrate interchangeability - a promise that it failed to keep - AbbVie is arguing a public hearing is needed before the agency acts on that vow1.

Advertisement
Advertisement
UsernamePublicRestriction

Register